Detection of chemotherapy / radiation induced myocardial damage using modern CMR techniques

Not Applicable

• Conditions: C50.9; C81.9; Breast, unspecified; Hodgkin lymphoma, unspecified

• Registration Number: DRKS00009019
• Lead Sponsor: niklinik KölnInstitut für Diagnostische und Interventionelle Radiologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-08-17
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Patients with breast cancer and epirubicin-based chemotherapy with manifest chemotherapy-induced cardiomyopathy; patients with breast cancer and epirubicin-based chemotherapy without manifest chemotherapy-induced cardiomyopathy; patients with Hodgkin lymphoma before chemotherapy and / or mediastinal radiation therapy

Exclusion Criteria

MR contraindications (pacemakers, insulin pumps, artificial heart valves, cochlear implants, etc.); indication for a high-urgent treatment of cancer; known (not therapy-associated) heart diseases and manifest, hemodynamically relevant heart insufficiency

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
After acquisition of CMR data, all data (T1, T2, myocardial Strain, late enhancement, volumetric analyses) will be quantified by using various softwares. All data will be compared to the group of healthy volunteers.